💉

Sermorelin

Sermorelin is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary telling it to release a pulse of growth hormone. Most people take it for the downstream effects of higher GH and IGF-1: deeper sleep, faster recovery from training, gradual improvements in skin and body composition, and a general sense that the system is repairing itself better than it was. The audience is mostly adults over 35 watching their natural GH output decline with age and looking for a way to push it back up without going on full HGH.
The defining feature of sermorelin is how short-acting it is. It clears the blood in about 10-12 minutes, which means it produces one clean GH pulse and then disappears. This is the closest thing in the GHRH peptide family to mimicking what your own hypothalamus does at night, which is also why people pick it over
💉
CJC-1295
with DAC when they want the most physiological option. The trade-off is that it requires nightly injections and the effect is genuinely subtle. If you want a more aggressive push, longer-acting GHRH analogues exist.

Deep-dive

GH is released in pulses from the anterior pituitary under two opposing controls, GHRH (the gas pedal) and somatostatin (the brake), with ghrelin acting as a third input that amplifies the GHRH signal. Sermorelin is the 1-29 amino acid fragment of native human GHRH, the shortest portion that retains full receptor agonist activity. It binds the GHRH receptor on pituitary somatotrophs and triggers a GH pulse the same way endogenous GHRH does. Once the pulse hits, GH drives IGF-1 production in the liver and peripheral tissues, and IGF-1 mediates most of the anabolic, lipolytic, and tissue-repair effects people are actually after.
Pharmacokinetics. Sermorelin has a plasma half-life of about 11-12 minutes, cleared mainly by the enzyme DPP-IV. The GH pulse it produces peaks around 30-60 minutes after subcutaneous injection and returns to baseline within roughly 2 hours. This is the practical point that defines the compound: sermorelin produces one short, clean pulse on top of an otherwise low baseline, then leaves. It doesn't create the sustained background elevation that
💉
CJC-1295
with DAC does, which is the cleanest argument for using sermorelin over its longer-acting cousins, the pulse-vs-trough pattern is preserved and somatostatin feedback can still cycle normally between doses. The downside is that you have to inject nightly and the magnitude of any single pulse is smaller than what you'd get from the no-DAC CJC-1295 + ipamorelin stack.
Human clinical data, older adults. This is where sermorelin has the most actual evidence. The Vittone 1997 trial gave 11 healthy elderly men (average age 70) single nightly subcutaneous injections of GHRH 1-29 for 14 weeks. Nocturnal GH release rose significantly, and two of six muscle strength measures (upright row, shoulder press) and an abdominal endurance test improved. Mean systolic blood pressure dropped slightly. IGF-1 did not change significantly in this short study, which the authors attributed to insufficient duration. The Khorram 1997 trial ran longer, 16 weeks of nightly 10 µg/kg subcutaneous GHRH 1-29 in 9 men and 10 women aged 55-71. Twelve-hour integrated nocturnal GH levels rose significantly in both sexes, IGF-1 increased by roughly 28% within two weeks and stayed elevated for 12 weeks, IGFBP-3 went up, and men gained an average of 1.26 kg of lean body mass with measurable increases in skin thickness. Libido and general wellbeing also improved. This is the cleanest controlled trial showing that sermorelin meaningfully shifts body composition and IGF-1 in older adults, not just acute GH.
Cognition in older adults. The Vitiello 2006 trial ran 5 months of nightly sermorelin in 89 healthy older adults (average age 68) and found significant improvements on tests of problem solving, psychomotor processing speed, and working memory. There was no change on crystallized intelligence measures (vocabulary, general knowledge), which is expected, and the size of the cognitive benefit tracked with the size of the IGF-1 increase. Sex and oestrogen status didn't change the effect. This is a reasonably-sized RCT and it's the strongest cognitive evidence in the GHRH peptide class. Note that the Baker 2012 follow-up replicated and extended this in adults with mild cognitive impairment but switched to tesamorelin (a longer-acting GHRH 1-44 analogue) because of the larger and more sustained IGF-1 effect. Both compounds appear to help.
Pediatric growth hormone deficiency. Sermorelin was originally approved (as Geref) for diagnosing and treating pediatric GH deficiency. It worked, with improvements in height velocity comparable to recombinant GH in children whose deficiency was hypothalamic rather than pituitary. The drug was withdrawn from the US market in 2008 for commercial rather than safety reasons. This is relevant context: the safety profile in years of pediatric clinical use was clean, with the most common issue being mild injection-site reactions.
What you should and shouldn't expect. The pharmacokinetics are well-characterised and the older-adult body composition and cognition data are real. What's not there is large RCTs in healthy adults under 50, head-to-head comparisons against
💉
CJC-1295
+
💉
Ipamorelin
, long-term cancer or cardiovascular endpoint data, or any RCT measuring sleep architecture, skin metrics, or fat mass changes specifically attributable to sermorelin in younger users. Everything younger users are chasing (deeper sleep, faster recovery, skin) is either extrapolated from GH biology or comes from anecdote and peptide clinic experience. That doesn't mean it's wrong, the GH biology is solid, but the evidence base for sermorelin specifically is older-adult-heavy.
Why people pick sermorelin over the alternatives. Three reasons. One, it's the most physiologic of the GHRH peptides because the pulse is short and somatostatin feedback is preserved between doses. Two, it has more decades of human use than CJC-1295 or ipamorelin and a cleaner historical safety profile. Three, in the US it can be obtained legally through 503A compounding pharmacies with a prescription, which the longer-acting research peptides currently can't. The trade-off is potency, the no-DAC CJC-1295 + ipamorelin stack produces a bigger GH pulse and most people report stronger subjective effects on that combination. Sermorelin is the conservative, more-physiologic choice.
Anecdotal pattern. Across forums and peptide clinic reports, the most consistently reported effects are deeper sleep within the first 1-2 weeks (usually the first noticeable change), faster recovery between training sessions within the first month, and gradual improvements in skin firmness, hydration, nail and hair quality, and visceral fat reduction over 2-3 months. Less consistent: meaningful muscle gain (most people don't gain noticeable mass without also training and eating for it), libido changes, large fat loss. Common complaints: mild injection-site irritation, occasional facial flushing in the first 30-60 minutes after injection (the vasodilatory effect of GHRH receptor activation, usually fades after the first few doses), and dose-dependent water retention or tingling at the high end. Subjective effects tend to be milder and slower to build than what people report on the CJC-1295 + ipamorelin stack, which fits the pharmacology, smaller pulse, no ghrelin-pathway synergy.
Women. GH and IGF-1 biology is broadly similar between sexes but women have higher baseline GH pulse amplitude than men and a stronger response to oestrogen, which upregulates GH secretion. The two strongest sermorelin trials in older adults (Khorram 1997 and Vitiello 2006) both enrolled men and women in roughly equal numbers. Khorram showed equivalent or greater rises in nocturnal GH in women than men, similar IGF-1 increases, similar skin thickness gains, and reported improvements in wellbeing and libido in both sexes. The Vitiello cognition study explicitly tested whether sex or oestrogen status affected the cognitive benefit and found they did not. Practically, women use the same dose range as men, often starting at the lower end. Perimenopausal and postmenopausal women may notice the effects more because endogenous GH output declines alongside oestrogen and there's more room for an evoked pulse to register. The bone-density angle is particularly relevant in this group given the GH-IGF-1 axis's role in maintaining bone turnover. Skip sermorelin in pregnancy and breastfeeding, the GH/IGF-1 axis is tightly regulated during these periods and there's no safety data.
Older adults. GH output declines roughly 14% per decade after age 30. This is the population sermorelin was actually studied in, and it's where the evidence is strongest. The mechanism is sound because the pituitary's response to GHRH is preserved with age, the upstream signal is what drops. The long-term safety question is the weakest part of the picture, see the risks section for the IGF-1/cancer and glucose-handling considerations.
Limitations of the evidence. The two key older-adult RCTs are small (n=11 and n=19 in the body composition trials, n=89 in the cognition trial), the longest of them ran 5 months, and there's nothing larger or longer in the published literature. There are no RCTs in healthy adults under 50. The clinical use in pediatric GH deficiency provides decades of safety experience but doesn't speak to the body composition or longevity claims younger users care about. Most peptide manufacturers selling sermorelin online operate in a grey market, product purity and identity vary widely. Legally compounded sermorelin from a US 503A pharmacy is the cleanest source if you can access it, though even that sits in a regulatory grey zone, the FDA placed sermorelin on the 503A Category 2 list in 2023 alongside the other peptides citing immunogenicity and impurity concerns.

Dosage:

  • Standard dose: 100-500 mcg subcutaneous, nightly, before bed. Most people land at 200-300 mcg per dose. The clinical trials in older adults used 10 µg/kg (so around 700-1000 mcg for a 70-100 kg adult), which is on the high end of what most people use today
  • Timing: Inject 30-60 minutes before sleep on an empty stomach. Pre-bed dosing aligns with the natural nighttime GH surge during deep sleep and is the most effective single dose by far. Avoid food (especially carbs and protein) within 2 hours of injection, elevated insulin and circulating amino acids blunt the GH pulse via pituitary feedback
  • Higher doses don't produce more GH. The pituitary saturates around 200-500 mcg per pulse. Going higher produces more side effects (water retention, tingling, lethargy) without more GH output. Frequency over single-dose magnitude is the better lever if you want more total stimulus, though most people stick with once-nightly
  • Cycling: Most protocols run 3-6 months on, then 4-8 weeks off. The off period lets the IGF-1 set point reset and gives you a window to recheck fasting glucose, HbA1c, and IGF-1. Indefinite continuous use isn't well-studied even in the older-adult trials, the longest of which ran 5 months
  • Women: Same dose range as men, often starting at the lower end (100-200 mcg). Perimenopausal and postmenopausal women tend to notice effects faster because endogenous GH baseline is lower
  • Reconstitution: Comes as lyophilised powder, reconstitute with bacteriostatic water, store refrigerated, and use within 30 days. Some sources say 14 days for sermorelin specifically because it's less stable in solution than the modified GHRH analogues. Subcutaneous injection into abdominal fat or thigh with an insulin syringe. Rotate sites
  • Stacks: Sermorelin is often combined with
    💉
    Ipamorelin
    for the GHRH + ghrelin synergy, the same logic as the no-DAC CJC-1295 + ipamorelin stack but with a more physiologic GHRH pulse. Most people running this combination use 100-200 mcg of each pre-bed. Stacking with exogenous HGH is redundant and shuts down the natural pulse

Here's what you can expect:

The first thing most people notice, usually within the first 1-2 weeks, is deeper sleep. This is the most consistent early signal and the one with the most physiological sense (the natural nocturnal GH pulse is a known contributor to slow-wave sleep). Recovery between training sessions tends to feel faster within the first month. Skin firmness and hydration improvements come gradually over 2-3 months, similar in timeline to
GHK-Cu
GHK-Cu
but driven by IGF-1 rather than direct fibroblast signalling. Body composition changes (modest visceral fat reduction, lean mass preservation or gain) build over 3-6 months and require that you're also training and eating reasonably, this isn't a body-recomposition compound on its own.
If you're under 40 and well-trained, the subjective effect may be quite subtle, the older-adult data is strong partly because the GH/IGF-1 baseline is so much lower in that group and there's more headroom. If you're not noticing anything after 6-8 weeks at a standard dose, the product is likely under-dosed, degraded, or you have less GH/IGF-1 headroom than you think. Grey-market sourcing variance is the most common cause of "I felt nothing" reports.

Side effects & risks:

  • Injection site reactions are by far the most common side effect, mild redness, itching, occasional bruising. Rotate sites
  • Facial flushing and warmth in the first 30-60 minutes after injection. This is the vasodilatory effect of GHRH receptor activation and is harmless. Usually fades after the first few doses
  • Headache and lethargy at higher doses or if dosed too late and the GH pulse runs into the morning. Pull the dose back
  • Mild water retention and tingling (paraesthesia) in hands and feet at the upper end of the dose range. Early sign of carpal tunnel-type symptoms from elevated GH/IGF-1. Reversible. Reduce dose
  • Insulin resistance and elevated fasting glucose. GH is counter-regulatory to insulin and sustained elevation pushes fasting glucose and HbA1c up. Most people see modest changes, but it matters if you already have prediabetes or metabolic syndrome. Recheck at 3 months. The pulsatile, short-acting nature of sermorelin probably makes this milder than with long-acting analogues, but the underlying biology is the same
  • Active or recent cancer, avoid. IGF-1 is mitogenic and elevated IGF-1 levels are epidemiologically associated with increased risk of several cancers (colorectal, prostate, breast) over long timescales. Hard contraindication if you have a current or recent cancer diagnosis
  • Diabetic retinopathy can worsen with elevated GH/IGF-1. Avoid if you have any active diabetic eye disease
  • Sleep apnoea can worsen with GH elevation due to soft tissue changes, monitor if you have it
  • Pregnancy and breastfeeding: avoid
  • Pituitary tumour or unexplained hyperprolactinaemia: avoid until worked up
  • Hypothyroidism: GH stimulation can unmask underlying low thyroid output. If you're symptomatic for hypothyroidism, screen before starting
  • Long-term safety data is limited. The longest controlled human trials in adults ran 5 months. Pediatric experience is more extensive but doesn't translate directly to the older-adult use case. Beyond 6 months, you're inferring safety from related GH literature
  • Sourcing. In the US, legitimate sermorelin is available through 503A compounding pharmacies with a prescription, which is the cleanest source. Grey-market product sold online for "research use" varies widely in purity and dose accuracy. If a product produces strong unexpected effects (severe hunger, anxiety, fluid retention out of proportion to dose) it may be contaminated with another peptide. Third-party tested sources are worth the premium
  • Regulatory status: Sermorelin was FDA-approved as Geref but withdrawn from the US market in 2008 for commercial reasons. As of 2026 it sits on the FDA 503A Category 2 list (added 2023, status under PCAC review) but is still being compounded by many 503A pharmacies under prescription. WADA prohibits it in competition

🩸

Blood markers

IGF-1, baseline and at 6-8 weeks. The most useful single marker for whether the compound is working and at what intensity. Aim for the upper end of the age-adjusted reference range, not above it. Sermorelin typically produces smaller IGF-1 rises than CJC-1295 with DAC because the pulses are shorter and there's no sustained elevation.
Fasting glucose and HbA1c, baseline and at 3 months. The metabolic cost of sustained GH elevation. If fasting glucose creeps above 100 mg/dL or HbA1c above 5.7%, reduce dose or stop.
Fasting insulin and HOMA-IR, baseline if you want a more sensitive read on insulin resistance than glucose alone. Recheck at 3 months.
Full lipid panel, baseline. Recheck at 3 months. GH and IGF-1 can shift lipid markers in either direction.
TSH, free T4, free T3, baseline. GH can suppress TSH and shift T4 to T3 conversion. Worth knowing if you have thyroid history.
Prolactin and cortisol, baseline. Mostly to rule out a pituitary issue before pushing the axis. Sermorelin itself doesn't meaningfully affect prolactin or cortisol.
For most people the practical minimum is IGF-1 + fasting glucose + HbA1c at baseline and at 3 months. Everything else is for completeness or troubleshooting.

Related compounds without dedicated pages yet:
Tesamorelin
No dedicated page yet, worth adding.
MK-677 (Ibutamoren)
No dedicated page yet, worth adding.
GHRP-2 and GHRP-6
No dedicated page yet, worth adding.
Hexarelin
No dedicated page yet, worth adding.
HGH (recombinant somatropin)
No dedicated page yet, worth adding.
In the US, sermorelin is available by prescription through 503A compounding pharmacies. Not approved for human use in most other jurisdictions and most online sources are sold as research chemicals.